<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01854125</url>
  </required_header>
  <id_info>
    <org_study_id>NanjingPLAGH1</org_study_id>
    <secondary_id>Jinling 01</secondary_id>
    <nct_id>NCT01854125</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites</brief_title>
  <official_title>Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) is the final destiny in chronic liver disease.The quality of life in
      liver cirrhosis patients with refractory ascites are very wretched. The objective of this
      study is to evaluate the therapeutic efficacy of autologous bone marrow mesenchymal stem
      cells (BMSCs) transplantation via liver artery in Child-Pugh B and C stage of liver cirrhosis
      patients with refractory ascites. The immunomodulatory impact of MSCs in fibrosis was
      confirmed, and several clinical studies have applied MSCs to eliminate the progression of
      fibrosis. In this research the investigators will study the affect and influence of MSCs in
      the patients,include assay of liver function,variation of ascites,Child-Pugh score etc.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in immune function,liver function in blood</measure>
    <time_frame>before and one to 12 weeks after therapy</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Function in Blood</condition>
  <condition>Liver Function in Blood</condition>
  <condition>Variation of Ascites</condition>
  <condition>Characters of Quality of Life</condition>
  <condition>Child-Pugh Score</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Every patient is given 1x106 MSCs per kg infused via liver artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stem cells transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mesenchymal stem cells transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow mesenchymal stem cells transplantation</intervention_name>
    <description>Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.</description>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>stem cells transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous bone marrow msenchymal stem cells transplantation</intervention_name>
    <arm_group_label>autologous bone marrow mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>mesenchymal stem cells transplantation</arm_group_label>
    <arm_group_label>stem cells transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Inclusion Criteria:

        Aged 18~65 years. Ultrasonographic evidences of cirrhosis. hepatic cirrhosis patients with
        refractory ascite.

        Exclusion Criteria:

        history of moderate to severe hepatic encephalopathy or variceal bleeding during the last
        two months before enrolment.

        Prothrombin time is less than 30s. Severe problems in other vital organs(e.g.the
        heart,renal or lungs). Liver tumor on ultrasonography, CT or MRI examination. Pregnant or
        lactating women. Imaging evidences of vascular thromboses.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fangyu Wang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fangyu Wang, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nanjin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jinling Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kharaziha P, Hellstr√∂m PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1199-205. doi: 10.1097/MEG.0b013e32832a1f6c.</citation>
    <PMID>19455046</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2013</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Shihui</investigator_full_name>
    <investigator_title>Department of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <keyword>immun function</keyword>
  <keyword>liver function</keyword>
  <keyword>ascites</keyword>
  <keyword>quality of life</keyword>
  <keyword>Child-Pugh score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 11, 2015</submitted>
    <returned>April 29, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

